Recent changes
Track the most recent changes to the wiki on this page.
22 August 2019
| m 22:31 | Follicular lymphoma (diff | hist) . . (+973) . . Jwarner (talk | contribs) (→Rituximab monotherapy {{#subobject:ea91fc|Regimen=1}}) |
| m 22:26 | Rituximab (Rituxan) (diff | hist) . . (-8) . . Jwarner (talk | contribs) (→Also known as) |
| m 22:21 | Small cell lung cancer (diff | hist) . . (+709) . . Jwarner (talk | contribs) (→Cisplatin & Etoposide {{#subobject:ec90cd|Regimen=1}}) |
| 16:58 | Breast cancer (4 changes | history) . . (+7,487) . . [Jwarner (4×)] | ||
| m | 16:58 (cur | prev) . . (+2,666) . . Jwarner (talk | contribs) | ||
| 13:39 (cur | prev) . . (+2,541) . . Jwarner (talk | contribs) (→Cyclophosphamide monotherapy {{#subobject:fb7cyd|Regimen=1}}) | |||
| m | 13:25 (cur | prev) . . (+1,095) . . Jwarner (talk | contribs) (→Vinorelbine monotherapy {{#subobject:5c104c|Regimen=1}}) | ||
| 11:19 (cur | prev) . . (+1,185) . . Jwarner (talk | contribs) (→Paclitaxel & Bevacizumab {{#subobject:ab5252|Regimen=1}}) |
| m 15:55 | Breast cancer - historical (2 changes | history) . . (-2,102) . . [Jwarner (2×)] | ||
| m | 15:55 (cur | prev) . . (-1,117) . . Jwarner (talk | contribs) (→Paclitaxel monotherapy, q3wk {{#subobject:1cb87f|Regimen=1}}) | ||
| m | 15:45 (cur | prev) . . (-985) . . Jwarner (talk | contribs) (→Paclitaxel monotherapy, q3wk {{#subobject:1cb87f|Regimen=1}}) |
| 15:08 | Breast cancer, HER2-positive (2 changes | history) . . (+3,278) . . [Jwarner (2×)] | ||
| 15:08 (cur | prev) . . (+1,212) . . Jwarner (talk | contribs) (→Lapatinib & Trastuzumab {{#subobject:9be4d2|Regimen=1}}) | |||
| 08:55 (cur | prev) . . (+2,066) . . Jwarner (talk | contribs) (→Pertuzumab & Trastuzumab {{#subobject:b1d7b1|Regimen=1}}) |
| 08:20 | Breast cancer, ER/PR-positive (diff | hist) . . (+1,638) . . Jwarner (talk | contribs) (→Anastrozole & Goserelin {{#subobject:6e3249|Regimen=1}}) |
21 August 2019
| 22:18 | Breast cancer, ER/PR-positive (diff | hist) . . (+1,405) . . Jwarner (talk | contribs) (→Anastrozole & Fulvestrant {{#subobject:ae2512|Regimen=1}}) |
| 22:12 | Breast cancer, HER2-positive (2 changes | history) . . (+1,628) . . [Jwarner (2×)] | ||
| 22:12 (cur | prev) . . (+1,368) . . Jwarner (talk | contribs) (→Pertuzumab & T-DM1 {{#subobject:ffffbc|Regimen=1}}) | |||
| m | 14:11 (cur | prev) . . (+260) . . Jwarner (talk | contribs) |
| 19:37 | Esophageal cancer (3 changes | history) . . (+3,563) . . [Jwarner (3×)] | ||
| 19:37 (cur | prev) . . (+1,811) . . Jwarner (talk | contribs) (→Ramucirumab monotherapy {{#subobject:425b15|Regimen=1}}) | |||
| 19:34 (cur | prev) . . (+1,747) . . Jwarner (talk | contribs) (→Irinotecan & Mitomycin {{#subobject:dfc95f|Regimen=1}}) | |||
| m | 14:32 (cur | prev) . . (+5) . . Jwarner (talk | contribs) (→Chemotherapy) |
| m 15:08 | Small cell lung cancer - historical (3 changes | history) . . (+114) . . [Jwarner (3×)] | ||
| m | 15:08 (cur | prev) . . (+31) . . Jwarner (talk | contribs) (→Regimen {{#subobject:b2c397|Variant=1}}) | ||
| m | 15:08 (cur | prev) . . (0) . . Jwarner (talk | contribs) (→CEV (Carboplatin/Etoposide) {{#subobject:ec321a|Regimen=1}}) | ||
| m | 15:07 (cur | prev) . . (+83) . . Jwarner (talk | contribs) (→TEC {{#subobject:8703fa|Regimen=1}}) |
| m 14:36 | Multiple myeloma, relapsed/refractory (diff | hist) . . (+5) . . Jwarner (talk | contribs) (→Chemotherapy) |
| m 14:36 | Allogeneic HSCT (diff | hist) . . (+1) . . Jwarner (talk | contribs) |
| m 14:33 | Peripheral T-cell lymphoma (diff | hist) . . (+5) . . Jwarner (talk | contribs) |
| m 14:33 | Diffuse large B-cell lymphoma (diff | hist) . . (+5) . . Jwarner (talk | contribs) |
| m 11:36 | Ovarian cancer (diff | hist) . . (-24) . . Jwarner (talk | contribs) (→Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:3eae7f|Regimen=1}}) |
| m 11:36 | Melanoma (diff | hist) . . (-24) . . Jwarner (talk | contribs) |
| m 11:34 | Pancreatic cancer (diff | hist) . . (-24) . . Jwarner (talk | contribs) |
| m 11:34 | Gastric cancer (diff | hist) . . (+14) . . Jwarner (talk | contribs) |
| m 11:31 | Bladder cancer (diff | hist) . . (-19) . . Jwarner (talk | contribs) (→Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:fec6dd|Regimen=1}}) |
| m 11:30 | Breast cancer (diff | hist) . . (-499) . . Jwarner (talk | contribs) |
| m 11:06 | Uveal melanoma (diff | hist) . . (-12) . . Jwarner (talk | contribs) (→TACE monotherapy {{#subobject:f96a1b|Regimen=1}}) |
| m 11:06 | Hepatocellular carcinoma (diff | hist) . . (-24) . . Jwarner (talk | contribs) |
20 August 2019
| m 16:54 | Melanoma (diff | hist) . . (+637) . . Jwarner (talk | contribs) (→Talimogene laherparepvec monotherapy {{#subobject:PYR1|Regimen=1}}) |
| m 16:51 | Hepatocellular carcinoma (2 changes | history) . . (+1,369) . . [Jwarner (2×)] | ||
| m | 16:51 (cur | prev) . . (+697) . . Jwarner (talk | contribs) (→Sorafenib monotherapy {{#subobject:b38f69|Regimen=1}}) | ||
| m | 16:47 (cur | prev) . . (+672) . . Jwarner (talk | contribs) (→TACE monotherapy {{#subobject:f96a1b|Regimen=1}}) |
| m 16:34 | Follicular lymphoma (diff | hist) . . (+1,364) . . Jwarner (talk | contribs) (→Rituximab monotherapy, extended course {{#subobject:e26b69|Regimen=1}}) |
| m 16:23 | Colon cancer (3 changes | history) . . (+1,164) . . [Jwarner (3×)] | ||
| m | 16:23 (cur | prev) . . (+10) . . Jwarner (talk | contribs) | ||
| m | 16:22 (cur | prev) . . (+1,123) . . Jwarner (talk | contribs) (→Tegafur, Uracil, Folinic acid {{#subobject:5ed2aa|Regimen=1}}) | ||
| m | 16:19 (cur | prev) . . (+31) . . Jwarner (talk | contribs) (→Placebo) |
| m 13:46 | Head and neck cancer (diff | hist) . . (+1,506) . . Jwarner (talk | contribs) (→Radiation therapy {{#subobject:571927|Regimen=1}}) |
| m 11:59 | Non-small cell lung cancer (diff | hist) . . (+913) . . Jwarner (talk | contribs) (→Carboplatin & Gemcitabine {{#subobject:8669e|Regimen=1}}) |
| m 11:51 | Prostate cancer (diff | hist) . . (+752) . . Jwarner (talk | contribs) (→ADT & Enzalutamide {{#subobject:79lq3c|Regimen=1}}) |
| m 11:46 | Response to treatment (3 changes | history) . . (+53) . . [Jwarner (3×)] | ||
| m | 11:46 (cur | prev) . . (+55) . . Jwarner (talk | contribs) (→Neoadjuvant response rates) | ||
| m | 11:46 (cur | prev) . . (-54) . . Jwarner (talk | contribs) (→Progression-free survival rate at 6 months (PFS6)) | ||
| m | 11:46 (cur | prev) . . (+52) . . Jwarner (talk | contribs) (→Relapse-free interval (RFI)) |
| m 11:42 | Bladder cancer (diff | hist) . . (+1,318) . . Jwarner (talk | contribs) (→Locally advanced or metastatic disease, subsequent lines) |
19 August 2019
| m 22:49 | Non-small cell lung cancer (2 changes | history) . . (+3,041) . . [Jwarner (2×)] | ||
| m | 22:49 (cur | prev) . . (+1,537) . . Jwarner (talk | contribs) (→Carboplatin & Gemcitabine {{#subobject:7a8bcz|Regimen=1}}) | ||
| m | 22:46 (cur | prev) . . (+1,504) . . Jwarner (talk | contribs) (→Carboplatin & Pemetrexed {{#subobject:920f46|Regimen=1}}) |
| 20:08 | NTRK (diff | hist) . . (+1,880) . . Jwarner (talk | contribs) (→Larotrectinib monotherapy {{#subobject:e0d17a|Regimen=1}}) |
